Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Monopar Therapeutics Inc MNPR

Healthcare Biotechnology
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.


NDAQ:MNPR - Post by User

Monopar Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(229)
•••
Post by whytestockson Feb 27, 2024 9:30pm
69 Views
Post# 35902910

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical
Breaking News: $MNPR Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical TrialWILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that the internationally recognized radiopharmaceutical physician, Professor Rodn...MNPR - Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities